Cargando…

Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy

BACKGROUND: It is of great significance to develop intelligent co-delivery systems for cancer chemotherapy with improved therapeutic efficacy and few side-effects. MATERIALS AND METHODS: Here, we reported a co-delivery system based on pH-sensitive polyprodrug micelles for simultaneous delivery of do...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yanhua, Zhou, Yongjian, Zhang, Can Yang, Fang, Te
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227817/
https://www.ncbi.nlm.nih.gov/pubmed/32494132
http://dx.doi.org/10.2147/IJN.S249144
_version_ 1783534563410051072
author Jiang, Yanhua
Zhou, Yongjian
Zhang, Can Yang
Fang, Te
author_facet Jiang, Yanhua
Zhou, Yongjian
Zhang, Can Yang
Fang, Te
author_sort Jiang, Yanhua
collection PubMed
description BACKGROUND: It is of great significance to develop intelligent co-delivery systems for cancer chemotherapy with improved therapeutic efficacy and few side-effects. MATERIALS AND METHODS: Here, we reported a co-delivery system based on pH-sensitive polyprodrug micelles for simultaneous delivery of doxorubicin (DOX) and paclitaxel (PTX) as a combination chemotherapy with pH-triggered drug release profiles. The physicochemical properties, drug release profiles and mechanism, and cytotoxicity of PTX/DOX-PMs have been thoroughly investigated. RESULTS AND DISCUSSION: The pH-sensitive polyprodrug was used as nanocarrier, and PTX was encapsulated into the micelles with high drug-loading content (25.6%). The critical micelle concentration (CMC) was about 3.16 mg/L, indicating the system could form the micelles at low concentration. The particle size of PTX/DOX-PMs was 110.5 nm, and increased to approximately 140 nm after incubation for 5 days which showed that the PTX/DOX-PMs had high serum stability. With decrease in pH value, the particle size first increased, and thenwas no longer detectable. Similar change trend was observed for CMC values. The zetapotential increased sharply with decrease in pH. These results demonstrated the pHsensitivity of PTX/DOX-PMs. In vitro drug release experiments and study on release mechanism showed that the drug release rate and accumulative release for PTX and DOX were dependent on the pH, showing the pH-triggered drug release profiles. Cytotoxicity assay displayed that the block copolymer showed negligible cytotoxicity, while the PTX/DOX-PMs possessed high cytotoxic effect against several tumor cell lines compared with free drugs and control. CONCLUSION: All the results demonstrated that the co-delivery system based on pH-sensitive polyprodrug could be a potent nanomedicine for combination cancer chemotherapy. In addition, construction based on polyprodrug and chemical drug could be a useful method to prepare multifunctional nanomedicine.
format Online
Article
Text
id pubmed-7227817
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72278172020-06-02 Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy Jiang, Yanhua Zhou, Yongjian Zhang, Can Yang Fang, Te Int J Nanomedicine Original Research BACKGROUND: It is of great significance to develop intelligent co-delivery systems for cancer chemotherapy with improved therapeutic efficacy and few side-effects. MATERIALS AND METHODS: Here, we reported a co-delivery system based on pH-sensitive polyprodrug micelles for simultaneous delivery of doxorubicin (DOX) and paclitaxel (PTX) as a combination chemotherapy with pH-triggered drug release profiles. The physicochemical properties, drug release profiles and mechanism, and cytotoxicity of PTX/DOX-PMs have been thoroughly investigated. RESULTS AND DISCUSSION: The pH-sensitive polyprodrug was used as nanocarrier, and PTX was encapsulated into the micelles with high drug-loading content (25.6%). The critical micelle concentration (CMC) was about 3.16 mg/L, indicating the system could form the micelles at low concentration. The particle size of PTX/DOX-PMs was 110.5 nm, and increased to approximately 140 nm after incubation for 5 days which showed that the PTX/DOX-PMs had high serum stability. With decrease in pH value, the particle size first increased, and thenwas no longer detectable. Similar change trend was observed for CMC values. The zetapotential increased sharply with decrease in pH. These results demonstrated the pHsensitivity of PTX/DOX-PMs. In vitro drug release experiments and study on release mechanism showed that the drug release rate and accumulative release for PTX and DOX were dependent on the pH, showing the pH-triggered drug release profiles. Cytotoxicity assay displayed that the block copolymer showed negligible cytotoxicity, while the PTX/DOX-PMs possessed high cytotoxic effect against several tumor cell lines compared with free drugs and control. CONCLUSION: All the results demonstrated that the co-delivery system based on pH-sensitive polyprodrug could be a potent nanomedicine for combination cancer chemotherapy. In addition, construction based on polyprodrug and chemical drug could be a useful method to prepare multifunctional nanomedicine. Dove 2020-05-11 /pmc/articles/PMC7227817/ /pubmed/32494132 http://dx.doi.org/10.2147/IJN.S249144 Text en © 2020 Jiang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jiang, Yanhua
Zhou, Yongjian
Zhang, Can Yang
Fang, Te
Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
title Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
title_full Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
title_fullStr Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
title_full_unstemmed Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
title_short Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy
title_sort co-delivery of paclitaxel and doxorubicin by ph-responsive prodrug micelles for cancer therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227817/
https://www.ncbi.nlm.nih.gov/pubmed/32494132
http://dx.doi.org/10.2147/IJN.S249144
work_keys_str_mv AT jiangyanhua codeliveryofpaclitaxelanddoxorubicinbyphresponsiveprodrugmicellesforcancertherapy
AT zhouyongjian codeliveryofpaclitaxelanddoxorubicinbyphresponsiveprodrugmicellesforcancertherapy
AT zhangcanyang codeliveryofpaclitaxelanddoxorubicinbyphresponsiveprodrugmicellesforcancertherapy
AT fangte codeliveryofpaclitaxelanddoxorubicinbyphresponsiveprodrugmicellesforcancertherapy